Modafinil

Revision as of 08:45, 10 March 2014 by >Oskykins
Modafinil
noframe

Modafinil's 3D molecular structure.
Dosage (oral)
Threshold 0.5 - 1mg
Light 1 - 1.5mg
Common 1.5 - 2.5mg
Strong 2.5 - 5mg
Heavy 5+mg
Dosage (insufflated)
Threshold 0mg
Light 0 - 0mg
Common 0 - 0mg
Strong 0 - 0mg
Heavy 0 - 0mg
Duration (oral)
Onset 20 - 60 minutes
Come up 20 - 90 minutes
Peak 5 - 10 hours
Come down 1 - 3 hours
After effects 2 - 8 hours
Duration (insufflated)
Onset 0 - 0 minutes
Come up 0 - 0 minutes
Peak 0 - 0 hours
Come down 0 - 0 hours
After effects 0 - 0 hours

Modafinil (Provigil, Alertec, Modavigil) is a wakefulness promoting agent (eugeroic) used to enhance cognition, reduce fatigue, and increase alertness. It is approved by the United States' Food and Drug Administration for treatment of obstructive sleep apnea, shift work sleep disorder, and narcolepsy. [1]


Chemistry

Pharmacology

Subjective effects

Physical Effects

  • Physical effects: Stimulation
  • Dehydration
  • Physical effects: Appetite suppression
  • Physical effects: Headaches
  • Physical effects: Photophobia

Cognitive Effects

  • Increased Focus
  • Cognitive effects: Enhancement of memory
  • Cognitive effects: Increased motivation

Toxicity and Harm Potential

Lethal Dosage

Tolerance and Addiction Potential

  • In the United States, Modafinil is a Schedule IV controlled substance. It is illegal to buy, sell, or possess the drug without a prescription or DEA license. [2]
  • Modafinil is listed as a Schedule F prescription drug in Canada, meaning it can be prescribed for human and veterinary use. [3]

See Also

Nootropics

References

  1. Provigal (Manufacturer's Website) | http://www.provigil.com/
  2. Placement of Modafinil Into Schedule IV - U.S. Department of Justice | http://www.deadiversion.usdoj.gov/fed_regs/rules/1999/fr0127.htm
  3. National Association of Pharmacy Regulatory Authorities - Regulations Amending the Food and Drug Regulations (1184 — Modafinil) | http://napra.ca/Content_Files/Files/FDR-Project1184-Modafinil-Oct122006.pdf